These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29067742)

  • 1. Non-invasive evaluation of Secukinumab efficacy in severe plaque psoriasis with confocal microscopy and optical coherence tomography: A case report.
    Odorici G; Losi A; Ciardo S; Pellacani G; Conti A
    Skin Res Technol; 2018 Feb; 24(1):160-162. PubMed ID: 29067742
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT; Shojania K; Dutz J; Tsao NW
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.
    Cannavò SP; Postorino E; Aragona E; Bartolotta A; Papaianni V; Guarneri C
    J Dermatolog Treat; 2018; 29(sup1):9-11. PubMed ID: 30247938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response of secukinumab in palmoplantar psoriasis.
    Rocamora V; Garcías-Ladaria J
    Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab for the treatment of residual psoriasis: a case series.
    Malagoli P
    J Dermatolog Treat; 2018; 29(sup1):12-13. PubMed ID: 30919723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab in multi-failure psoriatic patients: the last hope?
    Magnano M; Loi C; Patrizi A; Sgubbi P; Balestri R; Rech G; Tasin L; Girardelli CR; Conti A; Odorici G; Campanati A; Offidani AM; Bardazzi F
    J Dermatolog Treat; 2018 Sep; 29(6):583-585. PubMed ID: 29334270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
    Blauvelt A; Reich K; Warren RB; Szepietowski JC; Sigurgeirsson B; Tyring SK; Messina I; Bhosekar V; Oliver J; Papavassilis C; Frueh J; Langley RGB
    Br J Dermatol; 2017 Sep; 177(3):879-881. PubMed ID: 28498514
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
    Georgakopoulos JR; Ighani A; Zhou LL; Yeung J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e32-e34. PubMed ID: 28695989
    [No Abstract]   [Full Text] [Related]  

  • 14. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
    Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
    Egeberg A; Iversen L; Gniadecki R; Hvid L; Dam TN; Bryld LE; Skov L
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1183-1187. PubMed ID: 28273375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis.
    Morgado-Carrasco D; Riera-Monroig J; Fustà-Novell X; Alsina Gibert M
    Actas Dermosifiliogr (Engl Ed); 2018; 109(6):565-567. PubMed ID: 29169562
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.
    Weng HJ; Wang TS; Tsai TF
    Br J Dermatol; 2018 Jun; 178(6):1439-1440. PubMed ID: 29265175
    [No Abstract]   [Full Text] [Related]  

  • 19. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
    Gottlieb A; Sullivan J; van Doorn M; Kubanov A; You R; Parneix A; Hugot S; Milutinovic M
    J Am Acad Dermatol; 2017 Jan; 76(1):70-80. PubMed ID: 27707593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
    Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
    J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.